Cardiovascular disease (CVD) is the leading cause of death worldwide, with CAD being the most common type, accounting for 49% of the 18.6 million CVD-related deaths in 2019.
The trial has been designed to improve understanding of the pathobiology of atherosclerotic cardiovascular diseases (ACVD) and how it varies between individuals, to aid the development of new treatments.
PlaqueTech will use its blood sampling device, the liquid biopsy system (LBS) to collect samples at multiple sites along a patient’s diseased coronary artery.
Thousands of proteins and other blood molecules will be measured in each sample, enabling the assessment of trans-plaque gradients between samples.
These data will be analysed and used to generate a more detailed picture of the disease and enhance clinicians' understanding of which proteins and biomolecules play key roles in CAD progression towards heart attack.
“A population approach to managing cardiovascular risk is generally used at present to treat CAD patients and prevent progression to heart attack, whereas a more tailored, precision medicine approach that accounts for each patient’s individual disease profile and health needs has exciting potential benefits. By better targeting of new therapies to those patients at highest risk and who most need them, we hope to efficiently stabilise their disease and improve outcomes,” said Dr Stephen Hoole, consultant cardiologist at Royal Papworth Hospital.
“The BIOPATTERN trial provides a novel opportunity to use the LBS device to help us better understand and characterise CAD on an individual patient level and potentially enable better patient care by identifying novel precision medicine targeted treatments to improve the outcome of patients with CAD in the future.”
Moving forward, the trial aims to recruit 300 patients with established CAD who have been scheduled for a coronary angiogram.
Patients will be recruited across eight UK NHS specialist cardiac centres, with four sites now open.
The study will assess the safety and functionality of the LBS device and confirm trans-plaque protein signals seen in earlier pilot studies.
If successful, PlaqueTec then aims to use the data collected to generate a new data platform based on novel site-of-disease insights to enable the stratification of patients with distinct disease endotypes and the development of precision medicine approaches to improve treatment outcomes for patients with CAD.
Dr Simon Williams, general manager at PlaqueTec, commented: “Reaching the 10-patient landmark and securing MHRA approval to continue to recruit to the BIOPATTERN trial is a huge success and enables us to pursue our ambition of opening a new frontier of precision medicine for patients with CAD. We are very grateful to all the patients and NHS site staff who have made this landmark possible and now look forward to progressing towards the 300-patient target.”
